CVnCoV and CV2CoV Protect Human ACE2 Transgenic Mice from Ancestral B BavPat1 and Emerging B.1.351 SARS-CoV-2

By
Justin.choi
-
0
151
The efficacy of spike encoding mRNA vaccines against the ancestral strain and the VOC B.1.351 was tested in a K18-hACE2 transgenic mouse model. Naive mice and mice immunized with a formalin-inactivated SARS-CoV-2 preparation were used as controls.
[Nature Communications]
Hoffmann, D., Corleis, B., Rauch, S., Roth, N., Mühe, J., Halwe, N. J., Ulrich, L., Fricke, C., Schön, J., Kraft, A., Breithaupt, A., Wernike, K., Michelitsch, A., Sick, F., Wylezich, C., Hoffmann, B., Thran, M., Thess, A., Mueller, S. O., … Beer, M. (2021). CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. Nature Communications, 12(1), 4048. https://doi.org/10.1038/s41467-021-24339-7 Cite
Full Article